A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123- Positive Hematologic Malignancies
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.